Viewing nowCombinationJanumet Tablets 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.

MFDS item code 202204365 · Approved 2022.12.05 · Insurance code 653806200
Improves glycemic control in patients with type 2 diabetes
This medication is used as an adjunct to diet and exercise to help control blood glucose levels in patients with type 2 diabetes who are using sitagliptin and metformin together. This helps effectively improve blood glucose levels and aids in diabetes management.
For antidiabetic therapy, the dose of this medicine should be determined by considering each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food, and the dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: In patients who have not previously received drug treatment for diabetes and for whom adequate glycemic control is difficult to achieve with monotherapy, or in patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of 50/500 mg twice daily; this may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients in whom administration is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current dose of metformin. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom administration is contraindicated).
This medication contains both sitagliptin and metformin hydrochloride to help regulate blood glucose levels. First, when taking this medication, severe allergic reactions may occur. If symptoms such as rash, difficulty breathing, or swelling of the face or lips develop, you must stop taking the medication immediately and consult a doctor. Moreover, serious side effects such as pancreatitis have been reported, so if symptoms like upper abdominal pain, vomiting, or nausea occur, you must visit a hospital immediately. Due to the metformin component, a rare but potentially fatal metabolic complication known as lactic acidosis can occur. Symptoms such as sudden fatigue, muscle pain, difficulty breathing, and abdominal pain should prompt immediate discontinuation of the medication and notification to the healthcare provider. Patients with poor kidney function or those suffering from acute illness, dehydration, or severe infections should not take this medication, and patients with impaired kidney function should undergo regular kidney function tests. This medication is not to be given to pregnant women or women who may become pregnant, nor to breastfeeding women. Additionally, this medication should be discontinued for a certain period before and after surgery, and only resumed after normal kidney function is confirmed post-surgery. While taking this medication, hypoglycemia may occur due to irregular meals, intense exercise, or interactions with other medications, so careful monitoring of blood glucose levels is necessary. Particularly when taken with insulin or sulfonylurea derivatives, the risk of hypoglycemia increases, and dose adjustments should be discussed with a doctor. During the course of treatment, side effects such as diarrhea, nausea, vomiting, headache, and upper respiratory infections may occur; if symptoms are severe or persistent, consult a healthcare provider. Lastly, avoiding excessive alcohol consumption while taking this medication is crucial, and regular blood tests and kidney function checks are essential to detect any signs early.
Anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is best to keep it at room temperature between 1 and 30 degrees Celsius, as this helps preserve the medication's effectiveness.
Dark red, oval film-coated tablets
56 tablets/box [(14 tablets/PTP x 4)], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.